Log In
BCIQ
Print this Print this
 

TAK-954 (formerly TD-8954)

  Manage Alerts
Collapse Summary General Information
Company Theravance Biopharma Inc.
DescriptionSerotonin (5-HT4) receptor agonist
Molecular Target Serotonin (5-HT4) receptor
Mechanism of ActionSerotonin (5-HT) receptor agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationGastrointestinal motility disorder
Indication DetailsTreat gastrointestinal (GI) motility disorder
Regulatory Designation U.S. - Fast Track (Treat gastrointestinal (GI) motility disorder)
PartnerTakeda Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$125.0M

$15.0M

$110.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/08/2016

$125.0M

$15.0M

$110.0M

Get a free BioCentury trial today